



Committed to Excellence in Healthcare



Lebanese University  
Faculty of Medical Sciences

# 1<sup>st</sup> Lebanese Oncology Forum

## 27 - 28 January 2017

Mount Lebanon Hospital, Gharios Medical Center



3 CE  
Credits



In collaboration with:



Lebanese Society of Medical Oncology  
الجمعية اللبنانية لأطباء الأورام الخبيث



LEBANESE UROLOGY SOCIETY  
الجمعية اللبنانية للمستشفيات البولية



Lebanese Society of Quality and Safety in Health Care  
الجمعية اللبنانية للمؤسسات الصحية



# GAZYVA® increases the impact of anti-CD20 therapy for patients with CLL and FL

## CLL

In first line<sup>1</sup>

### START WITH GAZYVA in CHRONIC LYMPHOCYTIC LEUKEMIA

## FL NOW APPROVED

After rituximab treatment<sup>1</sup>

### STRIKE BACK WITH GAZYVA in FOLLICULAR LYMPHOMA



**Abbreviated prescribing information:** GAZYVA (obinutuzumab) is a recombinant monoclonal humanized and glycosylated IgG1 anti-CD20 antibody of the IgG1 isotype. **Indications and potential uses:** GAZYVA is indicated for the treatment of CLL in combination with chlorambucil in patients with previously untreated CLL and follicular lymphoma (FL) in combination with rituximab in patients with relapsed or refractory CLL. GAZYVA is also indicated for the treatment of CLL in combination with chlorambucil in patients with previously untreated CLL and in combination with rituximab in patients with relapsed or refractory CLL. GAZYVA is also indicated for the treatment of FL in combination with rituximab in patients with relapsed or refractory FL. **Contraindications:** GAZYVA is contraindicated in patients with a known hypersensitivity to GAZYVA or any of its excipients. **Warnings and precautions:** GAZYVA may cause severe allergic reactions, including anaphylaxis, during or shortly after infusion. GAZYVA may cause severe infusion reactions, including anaphylaxis, during or shortly after infusion. GAZYVA may cause severe infusion reactions, including anaphylaxis, during or shortly after infusion. GAZYVA may cause severe infusion reactions, including anaphylaxis, during or shortly after infusion. **Adverse reactions:** GAZYVA may cause severe infusion reactions, including anaphylaxis, during or shortly after infusion. GAZYVA may cause severe infusion reactions, including anaphylaxis, during or shortly after infusion. **Use in specific populations:** GAZYVA may cause severe infusion reactions, including anaphylaxis, during or shortly after infusion. GAZYVA may cause severe infusion reactions, including anaphylaxis, during or shortly after infusion. **Storage:** GAZYVA should be stored at 2-8°C. GAZYVA should be stored at 2-8°C. **References:** 1. Gazyva Product Information. EMA May 2016.



Reference: 1. Gazyva Product Information. EMA May 2016.  
Full prescribing information is available upon request.  
In case of any adverse events occurring with Gazyva, please forward details to fax number: 00961-18-992664 or by email to: [ba1nu1\\_safety\\_reporting@roche.com](mailto:ba1nu1_safety_reporting@roche.com)  
Roche Lebanon SARL,  
Atrium Building, 37 Floor,  
33 Weygand Street,  
Bullak Central District, 11-5485  
Beirut, Lebanon  
©December 2016  
[www.roche-mideast.com](http://www.roche-mideast.com)



# 1<sup>st</sup> Lebanese Oncology Forum

27 - 28 January 2017  
Mount Lebanon Hospital, Gharios Medical Center



Committed to Excellence in Healthcare

Dear Colleagues,

Mount Lebanon Hospital -Gharios Medical Center, in collaboration with the Lebanese University – Faculty of Medical Sciences, the Lebanese Urology Society and the Lebanese Society of Medical Oncology, have the pleasure to invite you to its “First Lebanese Oncology Forum” which will be held on January 27-28, 2017 at the Mount Lebanon hospital.

A state of the art program addressing several oncological topics has been set. Hot topics discussing breast, colorectal, lung and prostatic cancers will be presented by renowned speakers.

On top enhancing cancer care through multidisciplinary approach will be tackled, as well as quality improvement through dedicated programs.

Your contribution through the interactive sessions and case presentation will be highly appreciated.

Sincerely,

Elie Gharios, MD  
Medical Director.



# 1<sup>st</sup> Lebanese Oncology Forum

27 - 28 January 2017  
Mount Lebanon Hospital, Gharios Medical Center



Committed to Excellence in Healthcare

## President of the Congress:

Dr. Elie Gharios

## Organizing Committee:

Dr. Gilbert El Helou

Dr. Marie Merheb

Dr. Fadi Nasr

Mrs. Roula Zahhar

## Scientific Committee:

Dr. Chantal Asmar

Dr. Gilbert El Helou

Dr. Fadi Farhat

Dr. Elie Gharios

Dr. Fadi Nasr

Dr. Ghazi Sakr

# KEYTRUDA<sup>®</sup>

(pembrolizumab) Injection 100 mg




## MSD Oncology

Azar Bldg, 2nd Floor Beirut, Lebanon  
Tel: +961 1 483300 Fax: +961 1 493300  
Full prescribing information is available upon request  
For further inquiries please email at:  
DPGC\_Levant@North.America.msx.merck.com  
JAN 2017 LEB ONCO-1173260-0000

# MORE SPECIAL MOMENTS

for Patients with Metastatic  
Pancreatic Cancer

The first tumour targeted *nab*<sup>™</sup> chemotherapy



## *Extending Survival to More Patients with Pancreatic Cancer*

Abraxane<sup>®</sup> (paclitaxel formulated as albumin bound nanoparticles) in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.<sup>1†</sup>

†Abraxane Therapeutic Indications also include:

- Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.
- Abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.

1. Abraxane<sup>®</sup>, Summary of Product Characteristics, July 2015

**Abraxane<sup>®</sup>**  
nanoparticle albumin bound paclitaxel



# 1<sup>st</sup> Lebanese Oncology Forum

27 - 28 January 2017  
Mount Lebanon Hospital, Gharios Medical Center



**Friday January 27<sup>th</sup> 2017**

08:30 - 09:00

**Welcome Note and Introduction**

Dr. Elie Gharios

Mount Lebanon Hospital Oncology Center : Future Objectives  
The Multidisciplinary Approach in Cancer Care a Key for Optimized  
Management Standards

## **Session 1: Advances in Breast Cancer - What's New?**

Moderators: Dr. Fadi Farhat - Dr. Ghassan Awar - Dr. Christina Khater

09:00 - 09:25

Breaking Protocols in the Adjuvant Treatment of Breast Cancer

Dr. Colette Hanna

09:25 - 09:50

Changing Treatment Paradigms in Metastatic Breast Cancer

Dr. Fadi Nasr

09:50 - 10:10

Genomics and Personalized Medicine in Breast Cancer

Dr. Adel Tabchy

10:10 - 10:30

The Management of Febrile Neutropenia

Dr. Nadine Yared

10:30 - 10:55

**Coffee Break**

## **Session 2: Enhancing Colorectal Cancer Care**

Moderators: Dr. Joseph Kattan - Dr. Henry Bitar - Dr. Raja Wakim

10:55 - 11:20

How does a tumor's location impact the surgical treatment and long-term outcomes for patients with colorectal cancer

Dr. Najib Gehchan

11:20 - 11:45

Colorectal Cancer A Multidisciplinary Approach to Individualized Patient Care

Dr. Fadi Farhat

## **Session 3: New Approaches in Lung Cancer**

Moderators: Dr. Carole Youwakim - Dr. Evelyn Helou

11:45 - 12:45

Current Treatment in First Line NSCLC: Where Do We Stand Today?  
*Lecture Sponsored by MSD*

Dr. Fadi Nasr

12:45 - 13:45

Role of Immunotherapy in Second Line NSCLC - Side Effects  
Management & Response Criteria Assessment  
*Lecture Sponsored by MSD*

Dr. Fadi Al Karak

13:45 - 14:45

**Lunch**



# 1<sup>st</sup> Lebanese Oncology Forum

27 - 28 January 2017  
Mount Lebanon Hospital, Gharios Medical Center



Committed to Excellence in Healthcare

14:45 - 15:05	The Role of EBUS in the Diagnosis of Lung Cancer	Dr. Dany Abou Abdallah
15:05 - 15:25	Radiation Therapy in Lung Cancer	Dr. Caroline Samaha
15:25 - 15:55	The Management of Pulmonary Aspergillosis in Immunocompromised Patients	Dr. Gilbert El Helou
15:55 - 16:45	What is the Place of the New Immunotherapy in Cancer? <i>Lecture Sponsored by BMS</i>	
15:55 - 16:15	Immunotherapy in Hodgkin Disease	Dr. Ali Bazarbachi
16:15 - 16:25	Immunotherapy in ENT Cancer	Dr. Francois Kamar
16:25 - 16:35	Immunotherapy in Renal Cell Carcinoma	Dr. Joseph Kattan
16:35 - 16:45	Second Line Place of Nivolumab in Lung Cancer	Dr. Fadi Nasr
16:45 - 17:15	Updates in The Management of Follicular Lymphoma <i>Lecture Sponsored by Roche</i>	Dr. Fadi Farhat
17:15 - 17:30	Coffee Break ( <i>Sponsored by Roche</i> )	
17:30 - 18:00	Opening Ceremony	
	Mr. Sleiman Haroun President of the Syndicate of Hospitals in Lebanon	
	Dr. Elie Gharios Medical Director Mount Lebanon Hospital	
	Dr. Raymond Sayegh President of the Lebanese Order of Physicians	

## Session 4 : Improving Health Quality : The Path Forward

Moderator: Dr. Nazih Gharios

18:00 - 18:20	Quality Improvement Programs in Mount Lebanon Hospital: Where are we in the National Quality Standards?	Mrs. Roula Zahar
18:20 - 18:40	Learning from Errors in Oncology	Dr. Rouba Rassi
18:40 - 19:10	Financial Burden of Cancer Drug Treatment in Lebanon	Dr. Fadia Elias







NOW THERE'S  
**OPDIVO**<sup>TM</sup>  
*(nivolumab)*

*Expect More. Do More.*

INJECTION FOR INTRAVENOUS USE 10mg/mL

**OPDIVO<sup>TM</sup> is indicated for the treatment of:<sup>1</sup>**

- Patients with unresectable or metastatic **Melanoma** in combination with ipilimumab.
- Patients with BRAF V600 "wild-type" or "mutation-positive" unresectable or metastatic **Melanoma** as a single agent.
- Patients with metastatic squamous and non-squamous non-small cell **Lung Cancer** (NSCLC) with progression on or after platinum-based chemotherapy.
- Advanced **Renal Cell Carcinoma** who have received prior anti-angiogenic therapy.
- **Classical Hodgkin Lymphoma** that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin.



Bristol-Myers Squibb

Laboratory Complex.  
Dubai Science Park  
P.O. Box: 454409, Dubai, UAE  
Tel: +971-4-4502100



# 1<sup>st</sup> Lebanese Oncology Forum

27 - 28 January 2017  
Mount Lebanon Hospital, Gharios Medical Center



Committed to Excellence in Healthcare

**Saturday January 28<sup>th</sup> 2017**

## **Session 1: Enhancing Prostate Cancer Care Through the Multidisciplinary Approach**

09:00 - 9:05	Welcome Note	Dr. Ghazi Sakr
	Moderators: Dr. Fadi Nasr - Dr. Ghazi Sakr - Dr. Maroun Serhal	
09:05 - 09:20	Role of PSMA Pet Scan in Prostate Cancer	Dr. Feras Chehadeh
09:20 - 09:35	MRI Fusion Biopsy: Impact on Diagnosis	Dr. Fouad Aoun
09:35 - 09:50	Oligo-metastatic Prostate Cancer: A new concept. A Paradigm shift?	Dr. Georges Assaf
09:50 - 10:05	Novel Therapeutic Techniques in Prostate Cancer	Dr. Georges Farha
10:05 - 10:35	Impact of the Multidisciplinary Approach to Prostate Cancer <i>Symposium Sponsored by Sanofi</i>	Dr. Raghid Khoury
10:35 - 11:05	Coffee Break	
11:05 - 11:25	Chemotherapy in Hormone Sensitive Prostate Cancer	Dr. Ali Shamseddine
11:25 - 11:45	Sequencing Therapy in CRPC	Dr. Joseph Kattan
11:45 - 12:25	Case Discussion	Dr. Mohamad Moussa Dr. Nehmeh Raad
12:25	Closing	Dr. Elie Gharios

The First Lebanese Oncology Forum would like to thank the following companies for their contribution to the success of the congress



Bristol-Myers Squibb

MSD Oncology



Biologix FZCO  
serviced by: Algorithm SAL



MERCK

UPO  
Union Pharmaceutique d'Orient s.a.l.



AMGEN



Organised by:



4<sup>th</sup> FLOOR, QUBIC CENTER, DAOUD AMMOUN STREET, HORSH TABET - SIN EL FIL  
P.O BOX: 90-361 BEIRUT, LEBANON | TEL: +961 1 510880/1/2/3 | FAX Ext. 121  
EMAIL: INFOMED@INFOMEDWEB.COM | WEB: WWW.INFOMEDWEB.COM